Brief: Poolbeg Pharma Says Polb 001 Patent Portfolio Was Granted U.S. Patent
08/03/2023 07:34
March 8 (Reuters) - Poolbeg Pharma PLC POLB.L :
* POOLBEG PHARMA PLC - POLB 001 PATENT PORTFOLIO
STRENGTHENED
THROUGH GRANTING OF US PATENT
* POOLBEG PHARMA PLC - PATENT GRANTED FOR USE OF CERTAIN P38
MAP
KINASE INHIBITORS FOR TREATMENT OF HYPERCYTOKINAEMIA
Source text for Eikon: ID:nRSH2727Sa
Further company coverage: POLB.L
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Poolbeg Pharma
See all newsBrief: Poolbeg Pharma Says European Patent Granted For POLB 001 In CRS
PDMR Notification
Brief: Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001
Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
Annual Report & AGM Notice